{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T21:17:53Z","timestamp":1790716673872,"version":"4.1.0"},"reference-count":51,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.jacl.2026.09.003","type":"journal-article","created":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T23:15:50Z","timestamp":1789427750000},"update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Association between lipoprotein(a) and structural degeneration of bioprosthetic aortic valves: A systematic review and meta-analysis"],"prefix":"10.1016","author":[{"given":"Ermilo","family":"Echeverr\u00eda-Orteg\u00f3n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mario C\u00e9sar","family":"Torres-Ch\u00e1vez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfredo P\u00e9rez-Tagle","family":"Tejeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0007-2263-4521","authenticated-orcid":false,"given":"Paulina","family":"Caballero","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Pastor-Cervantes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jacl.2026.09.003_bib1","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.jacc.2018.04.064","article-title":"Hemodynamic deterioration of surgically implanted Bioprosthetic aortic valves","volume":"72","author":"Salaun","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.003_bib2","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.120.018506","article-title":"Degeneration of bioprosthetic heart valves: update 2020","volume":"9","author":"Kostyunin","year":"2020","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.jacl.2026.09.003_bib3","doi-asserted-by":"crossref","DOI":"10.1093\/eurjpc\/zwaf681","article-title":"Association between lipoprotein(a), oxidized phospholipids, and bioprosthetic valve dysfunction following transcatheter aortic valve implantation","author":"Giuliani","year":"2025","journal-title":"Eur J Prev Cardiol"},{"key":"10.1016\/j.jacl.2026.09.003_bib4","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1016\/j.jacl.2019.04.010","article-title":"Use of lipoprotein(a) in clinical practice: a biomarker whose time has come. A scientific statement from the national lipid association","volume":"13","author":"Wilson","year":"2019","journal-title":"J Clin Lipidol"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.003_bib5","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1016\/j.jacc.2013.09.038","article-title":"Elevated lipoprotein(a) and risk of aortic valve stenosis in the general population","volume":"63","author":"Kamstrup","year":"2014","journal-title":"J Am Coll Cardiol"},{"issue":"6","key":"10.1016\/j.jacl.2026.09.003_bib6","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1056\/NEJMoa1109034","article-title":"Genetic associations with valvular calcification and aortic stenosis","volume":"368","author":"Thanassoulis","year":"2013","journal-title":"N Engl J Med"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.003_bib7","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.003_bib8","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1093\/eurheartj\/ehx033","article-title":"Lipoprotein(a): the revenant","volume":"38","author":"Gencer","year":"2017","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.09.003_bib9","doi-asserted-by":"crossref","first-page":"2150","DOI":"10.1016\/j.jacc.2019.01.070","article-title":"Lipoprotein(a) and oxidized phospholipids promote valve calcification in patients with aortic stenosis","volume":"73","author":"Zheng","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.003_bib10","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1186\/s13643-021-01626-4","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"10","author":"Page","year":"2021","journal-title":"Syst Rev"},{"issue":"39","key":"10.1016\/j.jacl.2026.09.003_bib11","doi-asserted-by":"crossref","first-page":"3968","DOI":"10.1093\/eurheartj\/ehac436","article-title":"Lipoprotein(a) and aortic valve stenosis: work in progress","volume":"43","author":"Kronenberg","year":"2022","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.09.003_bib12","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2021.105689","article-title":"Beyond lipoprotein(a) plasma measurements: lipoprotein(a) and inflammation","volume":"169","author":"Reyes-Soffer","year":"2021","journal-title":"Pharmacol Res"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.003_bib13","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.jjcc.2017.11.007","article-title":"Mechanisms of aortic stenosis","volume":"71","author":"Akahori","year":"2018","journal-title":"J Cardiol"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.003_bib14","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1161\/CIRCULATIONAHA.105.549311","article-title":"Glutaraldehyde-fixed bioprosthetic heart valve conduits calcify and fail from xenograft rejection","volume":"114","author":"Manji","year":"2006","journal-title":"Circulation"},{"issue":"7318","key":"10.1016\/j.jacl.2026.09.003_bib15","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/nature09421","article-title":"Oxidative stress induces angiogenesis by activating TLR2 with novel endogenous ligands","volume":"467","author":"West","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.jacl.2026.09.003_bib16","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1016\/j.yjmcc.2014.02.014","article-title":"P2Y2 receptor represses IL-6 expression by valve interstitial cells through Akt: implication for calcific aortic valve disease","volume":"72","author":"El Husseini","year":"2014","journal-title":"J Mol Cell Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.003_bib17","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1016\/j.yjmcc.2003.09.015","article-title":"Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulate aortic valve calcification","volume":"36","author":"Kaden","year":"2004","journal-title":"J Mol Cell Cardiol"},{"issue":"14","key":"10.1016\/j.jacl.2026.09.003_bib18","doi-asserted-by":"crossref","first-page":"12213","DOI":"10.1074\/jbc.M110.214619","article-title":"Oxidized low density lipoprotein induces bone morphogenetic protein-2 in coronary artery endothelial cells via Toll-like receptors 2 and 4","volume":"286","author":"Su","year":"2011","journal-title":"J Biol Chem"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.003_bib19","doi-asserted-by":"crossref","first-page":"1210","DOI":"10.1172\/JCI24140","article-title":"Msx2 promotes cardiovascular calcification by activating paracrine Wnt signals","volume":"115","author":"Shao","year":"2005","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jacl.2026.09.003_bib20","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1016\/j.yjmcc.2019.05.016","article-title":"Development of calcific aortic valve disease: do we know enough for new clinical trials?","volume":"132","author":"Kostyunin","year":"2019","journal-title":"J Mol Cell Cardiol"},{"issue":"8","key":"10.1016\/j.jacl.2026.09.003_bib21","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1016\/j.biomaterials.2005.08.003","article-title":"Stability and function of glycosaminoglycans in porcine bioprosthetic heart valves","volume":"27","author":"Lovekamp","year":"2006","journal-title":"Biomaterials"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.003_bib22","doi-asserted-by":"crossref","first-page":"1971","DOI":"10.1517\/14712598.4.12.1971","article-title":"Prevention of calcification in bioprosthetic heart valves: challenges and perspectives","volume":"4","author":"Simionescu","year":"2004","journal-title":"Expert Opin Biol Ther"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.003_bib23","doi-asserted-by":"crossref","first-page":"S406","DOI":"10.1016\/S0003-4975(01)02501-2","article-title":"Protein adsorption of calcified and noncalcified valvular bioprostheses after human implantation","volume":"71","author":"Shen","year":"2001","journal-title":"Ann Thorac Surg"},{"issue":"7","key":"10.1016\/j.jacl.2026.09.003_bib24","doi-asserted-by":"crossref","first-page":"2097","DOI":"10.1016\/j.biomaterials.2013.11.045","article-title":"The susceptibility of bioprosthetic heart valve leaflets to oxidation","volume":"35","author":"Christian","year":"2014","journal-title":"Biomaterials"},{"issue":"5","key":"10.1016\/j.jacl.2026.09.003_bib25","doi-asserted-by":"crossref","DOI":"10.1161\/JAHA.117.005648","article-title":"Calcification and oxidative modifications are associated with progressive bioprosthetic heart valve dysfunction","volume":"6","author":"Lee","year":"2017","journal-title":"J Am Heart Assoc"},{"issue":"6","key":"10.1016\/j.jacl.2026.09.003_bib26","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1111\/j.1365-2362.2009.02132.x","article-title":"Lipid-mediated inflammation and degeneration of bioprosthetic heart valves","volume":"39","author":"Shetty","year":"2009","journal-title":"Eur J Clin Invest"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.003_bib27","doi-asserted-by":"crossref","first-page":"544","DOI":"10.1016\/j.jacl.2025.03.001","article-title":"Association between lipoprotein(a) and long-term prognosis in patients receiving transcatheter aortic valve replacement","volume":"19","author":"Hu","year":"2025","journal-title":"J Clin Lipidol"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.003_bib28","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1016\/j.jacc.2015.07.020","article-title":"Oxidized phospholipids, lipoprotein(a), and progression of calcific aortic valve stenosis","volume":"66","author":"Capoulade","year":"2015","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.003_bib29","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1001\/jamacardio.2018.3798","article-title":"Association of mild to moderate aortic valve stenosis progression with higher lipoprotein(a) and oxidized phospholipid levels: secondary analysis of a randomized clinical trial","volume":"3","author":"Capoulade","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"10","key":"10.1016\/j.jacl.2026.09.003_bib30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1016\/j.jacasi.2024.07.007","article-title":"Association of lipoprotein(a) with severe degenerative aortic valve stenosis","volume":"4","author":"Kim","year":"2024","journal-title":"JACC Asia"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.003_bib31","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1001\/jamacardio.2017.4266","article-title":"Association of LPA variants with aortic stenosis: a large-scale study using diagnostic and procedural codes from electronic health records","volume":"3","author":"Chen","year":"2018","journal-title":"JAMA Cardiol"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.003_bib32","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCGENETICS.113.000400","article-title":"Lipoprotein(a) levels, genotype, and incident aortic valve stenosis: a prospective Mendelian randomization study and replication in a case-control cohort","volume":"7","author":"Arsenault","year":"2014","journal-title":"Circ Cardiovasc Genet"},{"issue":"10","key":"10.1016\/j.jacl.2026.09.003_bib33","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jcmg.2025.05.007","article-title":"Polymorphic size of lipoprotein(a) and structural bioprosthetic valve degeneration","volume":"18","author":"Capoulade","year":"2025","journal-title":"JACC Cardiovasc Imaging"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.003_bib34","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1093\/ejcts\/ezx244","volume":"52","author":"Capodanno","year":"2017","journal-title":"Eur J Cardiothorac Surg"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.003_bib35","doi-asserted-by":"crossref","DOI":"10.1016\/j.shj.2022.100155","article-title":"Structural valve deterioration in transcatheter aortic bioprostheses: diagnosis, pathogenesis, and treatment","volume":"7","author":"Patel","year":"2023","journal-title":"Struct Heart"},{"issue":"2","key":"10.1016\/j.jacl.2026.09.003_bib36","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1093\/ehjci\/jeaf320","article-title":"Lipoprotein(a) and long-term structural valve degeneration of aortic bioprostheses","volume":"27","author":"Boute","year":"2026","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"6","key":"10.1016\/j.jacl.2026.09.003_bib37","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1093\/ehjci\/jeac274","article-title":"Serum lipoprotein(a) and bioprosthetic aortic valve degeneration","volume":"24","author":"Botezatu","year":"2023","journal-title":"Eur Heart J Cardiovasc Imaging"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.003_bib38","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1136\/heartjnl-2023-322987","article-title":"Role of lipoprotein(a) concentrations in bioprosthetic aortic valve degeneration","volume":"110","author":"Farina","year":"2024","journal-title":"Heart"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.003_bib39","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.jcin.2017.01.017","article-title":"Bioprosthetic heart valves, thrombosis, anticoagulation, and imaging surveillance","volume":"10","author":"Bax","year":"2017","journal-title":"JACC Cardiovasc Interv"},{"key":"10.1016\/j.jacl.2026.09.003_bib40","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1016\/j.atherosclerosis.2022.04.006","article-title":"Non-genetic influences on lipoprotein(a) concentrations","volume":"349","author":"Enkhmaa","year":"2022","journal-title":"Atherosclerosis"},{"issue":"12","key":"10.1016\/j.jacl.2026.09.003_bib41","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1016\/j.amjcard.2003.08.066","article-title":"Effect of statins on the progression of bioprosthetic aortic valve degeneration","volume":"92","author":"Antonini-Canterin","year":"2003","journal-title":"Am J Cardiol"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.003_bib42","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ejcts.2009.06.051","article-title":"Postoperative lipid-lowering therapy and bioprosthesis structural valve deterioration: justification for a randomised trial?","volume":"37","author":"Kulik","year":"2010","journal-title":"Eur J Cardiothorac Surg"},{"issue":"21","key":"10.1016\/j.jacl.2026.09.003_bib43","doi-asserted-by":"crossref","first-page":"2054","DOI":"10.1016\/j.jacc.2022.08.787","article-title":"National trends in TAVR and SAVR for patients with severe isolated aortic stenosis","volume":"80","author":"Sharma","year":"2022","journal-title":"J Am Coll Cardiol"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.003_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.jacadv.2024.101311","article-title":"Treating aortic stenosis in young patients","volume":"3","author":"Sudhakaran","year":"2024","journal-title":"JACC Adv"},{"issue":"4","key":"10.1016\/j.jacl.2026.09.003_bib45","doi-asserted-by":"crossref","first-page":"181","DOI":"10.14740\/jocmr6196","article-title":"Lipoprotein(a)-lowering drugs: a mini review","volume":"17","author":"Hamasaki","year":"2025","journal-title":"J Clin Med Res"},{"issue":"11","key":"10.1016\/j.jacl.2026.09.003_bib46","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1016\/j.jacc.2021.12.032","article-title":"Effect of pelacarsen on lipoprotein(a) cholesterol and corrected low-density lipoprotein cholesterol","volume":"79","author":"Yeang","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.jacl.2026.09.003_bib47","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ahj.2025.03.019","article-title":"Design and rationale of Lp(a)HORIZON trial: assessing the effect of lipoprotein(a) lowering with pelacarsen on major cardiovascular events in patients with CVD and elevated Lp(a)","volume":"287","author":"Cho","year":"2025","journal-title":"Am Heart J"},{"issue":"3","key":"10.1016\/j.jacl.2026.09.003_bib48","doi-asserted-by":"crossref","first-page":"1187","DOI":"10.1007\/s10557-025-07810-1","article-title":"Lipoprotein(a) in cardiovascular diseases and emerging therapeutic strategies","volume":"40","author":"Al-Horani","year":"2026","journal-title":"Cardiovasc Drugs Ther"},{"key":"10.1016\/j.jacl.2026.09.003_bib49","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ahj.2022.05.004","article-title":"Study design and rationale for the Olpasiran trials of Cardiovascular Events And lipoproteiN(a) reduction-DOSE finding study (OCEAN(a)-DOSE)","volume":"251","author":"O'Donoghue","year":"2022","journal-title":"Am Heart J"},{"issue":"21","key":"10.1016\/j.jacl.2026.09.003_bib50","doi-asserted-by":"crossref","first-page":"2075","DOI":"10.1001\/jama.2023.21835","article-title":"Lepodisiran, an extended-duration short interfering RNA targeting lipoprotein(a): a randomized dose-ascending clinical trial","volume":"330","author":"Nissen","year":"2023","journal-title":"JAMA"},{"issue":"1","key":"10.1016\/j.jacl.2026.09.003_bib51","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1007\/s12170-025-00759-8","article-title":"Current clinical trials for treating elevated lipoprotein(a)","volume":"19","author":"De Los Reyes","year":"2025","journal-title":"Curr Cardiovasc Risk Rep"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005155?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426005155?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T20:43:33Z","timestamp":1790714613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426005155"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":51,"alternative-id":["S1933287426005155"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.003","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Association between lipoprotein(a) and structural degeneration of bioprosthetic aortic valves: A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.09.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}